Assistant Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Brian M. Wolpin, MD
|
|
Give Review
Brian Wolpin works in the field of Oncology. He attended Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1 in research and 12 in primary care medicine Brian Wolpin is also published. He has 54 publications published. The lastest publication: "A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers.' He is registered with Medicare.
Publications
- Characterization of large structural genetic mosaicism in human autosomes.
- Elevation of circulating branched-chain amino acids is an early event in human Pancreatic adenocarcinoma development.
- Genome-wide association study identifies multiple susceptibility loci for pancreatic Cancer.
- A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
- Imputation and subset based association analysis across different Cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.
- Variants associated with susceptibility to pancreatic Cancer and melanoma do not reciprocally affect risk.
- Correlation of CT patterns of primary intrahepatic cholangiocarcinoma at the time of presentation with the metastatic spread and clinical outcomes: retrospective study...
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma.
- Nut consumption and risk of pancreatic Cancer in women.
- Hyperglycemia, Insulin Resistance, Impaired Pancreatic β-Cell Function, and Risk of Pancreatic Cancer.
- Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic Cancer.
- Inflammatory plasma markers and pancreatic Cancer risk: a prospective study of five u.s. Cohorts.
- Multi-drug inhibition of the HER pathway in metastatic colorectal Cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.
- Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
- Feasibility of computer-based self-administered Cancer-specific geriatric assessment in older patients with gastrointestinal malignancy.
- Diabetes and risk of pancreatic Cancer: a pooled analysis from the pancreatic Cancer cohort consortium.
- A Prospective Study of Plasma Adiponectin and Pancreatic Cancer Risk in Five US Cohorts.
- Molecular pathological epidemiology of epigenetics: emerging integrative science to Analyze environment, host, and disease.
- Genome-wide association study of survival in patients with Pancreatic adenocarcinoma.
- Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced Neuroendocrine tumors.
- ABO blood group and risk of coronary heart disease in two prospective cohort studies.
- Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer.
- Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer.
- A phase 2 study of oral MKC-1, an inhibitor of importin-?, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic Cancer.
- Dietary insulin load, dietary insulin index, and risk of pancreatic Cancer.
- ABO blood group and breast Cancer incidence and survival.
- ABO Blood Group and Risk of Colorectal Cancer.
- ABO blood group and incidence of epithelial ovarian Cancer.
- Variant ABO blood group alleles, secretor status, and risk of pancreatic Cancer: results from the pancreatic Cancer cohort consortium.
- Family history of Cancer and risk of pancreatic Cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan).
- A step forward in the treatment of advanced biliary tract Cancer.
- A genome-wide association study identifies pancreatic Cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.
- Pancreatic Cancer risk and ABO blood group alleles: results from the pancreatic Cancer cohort consortium.
- Clinical problem-solving. The writing on the wall.
- Interactive medical case. The writing on the wall.
- Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic Cancer.
- A cohort study of STMN1 expression in colorectal Cancer: body mass index and prognosis.
- Defining determinants of pancreatic Cancer risk: are we making progress?
- A cohort study of p27 localization in colon Cancer, body mass index, and patient survival.
- ABO blood group and the risk of pancreatic Cancer.
- Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal Cancer.
- Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic Cancer.
- Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal Cancer: results from intergroup trial N9741.
- Prediagnostic plasma folate and the risk of death in patients with colorectal Cancer.
- Systemic treatment of colorectal Cancer.
- Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic Cancer.
- Adjuvant treatment of colorectal Cancer.
- Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal Cancer.
- Learning to cope: how far is too close?
- Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
- An absolute risk model to identify individuals at elevated risk for pancreatic Cancer in the general population.
- Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic Cancer may not impact local control.
- A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric Cancers.
Schools
Harvard Medical School
Harvard Med
Dana Farber Cancer Institute Harvard Med
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1922066893 | |
| NPPES Provider LastName | WOLPIN | |
| NPPES Provider FirstName | BRIAN | |
| NPPES Provider ZIPCode | 02215 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 111.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1922066893 |
| Last Name Of The Provider | WOLPIN |
| First Name Of The Provider | BRIAN |
| View All |
Similar Doctors
|
|
Dr. Wei Wang, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew J. Aguirre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suniti N. Nimbkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert W. Ross, MD |
|
|
Dr. Stephen M. Rothenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc B. Garnick, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Channing Yu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimmie Ng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam J. Bass, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Sweeney, MD |
|
|
Dr. Katherina Z. Calvillo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John R. Clark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee M. Nadler, MD
This Doctor is OpenDoctor Recommended.
|